Cargando…
Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers
Background: The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood. Materials and Methods: We retrospectively identified patients with ERBB2 CNG on commercial NGS. We...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809397/ https://www.ncbi.nlm.nih.gov/pubmed/35126865 http://dx.doi.org/10.18632/oncotarget.28188 |
_version_ | 1784644004013408256 |
---|---|
author | Shah, Ami N. Sunderraj, Ashwin Finkelman, Brian See, Sharlene H. Davis, Andrew A. Gerratana, Lorenzo Wehbe, Firas Katam, Neelima Mahalingam, Deva Gradishar, William J. Behdad, Amir Blanco, Luis Cristofanilli, Massimo |
author_facet | Shah, Ami N. Sunderraj, Ashwin Finkelman, Brian See, Sharlene H. Davis, Andrew A. Gerratana, Lorenzo Wehbe, Firas Katam, Neelima Mahalingam, Deva Gradishar, William J. Behdad, Amir Blanco, Luis Cristofanilli, Massimo |
author_sort | Shah, Ami N. |
collection | PubMed |
description | Background: The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood. Materials and Methods: We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing. Results: 176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast (n = 67), non-small cell lung (n = 25), colorectal (n = 18), gastroesophageal (n = 17), pancreatic (n = 11), and uterine (n = 11). The PPV of ERBB2 CNG in determining HER2 positivity by standard IHC/FISH definitions was 88% for tissue NGS (n = 57) and 80% for ctDNA (n = 47). The PPV among breast cancer patients for tissue NGS was 97% (n = 35) and ctDNA was 93% (n = 39). However, for non-breast cancer cases, the PPV of ERBB2 amplification by tissue NGS dropped to 76% (n = 22) and by ctDNA to 44% (n = 7). Conclusions: ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer. |
format | Online Article Text |
id | pubmed-8809397 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-88093972022-02-03 Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers Shah, Ami N. Sunderraj, Ashwin Finkelman, Brian See, Sharlene H. Davis, Andrew A. Gerratana, Lorenzo Wehbe, Firas Katam, Neelima Mahalingam, Deva Gradishar, William J. Behdad, Amir Blanco, Luis Cristofanilli, Massimo Oncotarget Research Paper Background: The correlation of ERBB2 copy number gain (CNG) from tissue or circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) with standard HER2 tissue evaluation is not well understood. Materials and Methods: We retrospectively identified patients with ERBB2 CNG on commercial NGS. We described their clinical-pathologic features and calculated the positive predictive value (PPV) of ERBB2 CNG by NGS for HER2-positivity by IHC and FISH testing. Results: 176 patients had NGS revealing an ERBB2 CNG (112 by tumor tissue and 91 by ctDNA). The cancer subtypes with the most cases with ERBB2 CNG by NGS were breast (n = 67), non-small cell lung (n = 25), colorectal (n = 18), gastroesophageal (n = 17), pancreatic (n = 11), and uterine (n = 11). The PPV of ERBB2 CNG in determining HER2 positivity by standard IHC/FISH definitions was 88% for tissue NGS (n = 57) and 80% for ctDNA (n = 47). The PPV among breast cancer patients for tissue NGS was 97% (n = 35) and ctDNA was 93% (n = 39). However, for non-breast cancer cases, the PPV of ERBB2 amplification by tissue NGS dropped to 76% (n = 22) and by ctDNA to 44% (n = 7). Conclusions: ERBB2 CNG by NGS is detected in numerous malignancies for which HER2 testing is not standard. Detection of ERBB2 CNG by tissue NGS and ctDNA has a high PPV for true HER2-positivity by standard IHC and/or FISH testing in breast cancer. Impact Journals LLC 2022-02-02 /pmc/articles/PMC8809397/ /pubmed/35126865 http://dx.doi.org/10.18632/oncotarget.28188 Text en Copyright: © 2022 Shah et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Shah, Ami N. Sunderraj, Ashwin Finkelman, Brian See, Sharlene H. Davis, Andrew A. Gerratana, Lorenzo Wehbe, Firas Katam, Neelima Mahalingam, Deva Gradishar, William J. Behdad, Amir Blanco, Luis Cristofanilli, Massimo Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title | Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title_full | Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title_fullStr | Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title_full_unstemmed | Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title_short | Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers |
title_sort | positive predictive value of erbb2 copy number gain by tissue or circulating tumor dna next-generation sequencing across advanced cancers |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809397/ https://www.ncbi.nlm.nih.gov/pubmed/35126865 http://dx.doi.org/10.18632/oncotarget.28188 |
work_keys_str_mv | AT shahamin positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT sunderrajashwin positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT finkelmanbrian positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT seesharleneh positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT davisandrewa positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT gerratanalorenzo positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT wehbefiras positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT katamneelima positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT mahalingamdeva positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT gradisharwilliamj positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT behdadamir positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT blancoluis positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers AT cristofanillimassimo positivepredictivevalueoferbb2copynumbergainbytissueorcirculatingtumordnanextgenerationsequencingacrossadvancedcancers |